Top-News
Professionelle Dienstleistungen USA

Vera Therapeutics Inc News

Aktie
WKN:  A3CPQG ISIN:  US92337R1014 US-Symbol:  VERA
43,47 $
+1,17 $
+2,77%
21:59:59 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
54,45 Mio.
Marktkapitalisierung *
2,15 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.04.2024

Vera Therapeutics Inc News

25.01.24 - PR Newswire
Thinking about trading options or stock in TAL Education, Vera Therapeutics, MarineMax, General Motors, or Boyd Gaming?
Thinking about trading options or stock in TAL Education, Vera Therapeutics, MarineMax, General Motors, or Boyd Gaming? PR Newswire
20.06.23 - PR Newswire
Thinking about buying stock in iCAD, Voxeljet, NeoVolta, Vera Therapeutics, or Nio Inc?
Thinking about buying stock in iCAD, Voxeljet, NeoVolta, Vera Therapeutics, or Nio Inc? PR Newswire
12.06.23 - PR Newswire
Thinking about trading options or stock in Xpeng Inc, Apple, NVIDIA, Chinook Therapeutics, or Vera Therapeutics?
Thinking about trading options or stock in Xpeng Inc, Apple, NVIDIA, Chinook Therapeutics, or Vera Therapeutics? PR Newswire
06.02.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA PR Newswire
20.01.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA PR Newswire
12.01.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Therapeutics, Inc. - VERA PR Newswire

Newssuche

Videos

newspaper
30.04.24 +18,03%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »